A first-in-human study to investigate the safety, tolerability, pharmacokinetics, and pharmacodynamics of KM-819 (FAS-associated factor 1 inhibitor), a drug for Parkinson’s disease, in healthy volunteers
2019 ◽
Vol Volume 13
◽
pp. 1011-1022
◽
Keyword(s):
2018 ◽
Vol 16
(9)
◽
pp. 1722-1731
◽
1991 ◽
Vol 40
(4)
◽
pp. 399-403
◽
2008 ◽
Vol 65
(3)
◽
pp. 338-346
◽
Keyword(s):